Investors are greeting President Trump's nomination of Kevin Warsh to lead the Federal Reserve with cautious approval, while weighing key questions about how the former Fed governor's crisis-era ...

Across the recent three months, 4 analysts have shared their insights on Automatic Data Processing (NASDAQ:ADP), expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

Each year, I take a look at the Minnesota Vikings first-round picks throughout the NFL Draft process. The mock draft tracker gives us some really good data on how the industry thinks the Vikings will ...

In a recent interview with Schwab Network, analysts discussed the potential impact of Microsoft Corporation (NASDAQ: MSFT) Azure on Alphabet Inc.’s (NASDAQ: GOOGL) Google AI business and why they ...

Nicole Charky-Chami is a senior editor based in Los Angeles, writing and producing breaking news. She teaches journalism courses for UCLA Extension and previously taught at Loyola Marymount University ...

Chris Mooney is a Pulitzer Prize-winning journalist and a CNN Climate contributor. He is currently a professor of practice in the Environmental Institute at the University of Virginia. Planet-warming ...

Shares of Palantir continued their impressive run in 2025. Alibaba and AMD are both positioned to accelerate their revenue growth in key AI segments. Their stock valuations are far more compelling ...

Advanced Micro Devices AMD shares have jumped 70.3% in the past year, outperforming the Zacks Computer and Technology sector’s 24.7% return and the Zacks Computer – Integrated Systems industry’s ...

Marvell clearly has visibility into big financial opportunities, but analysts wonder about its competitive positioning and the impact of a newly announced deal Marvell's stock was up about 8% on ...

Marvell Technology’s upbeat guidance had Wall Street cheering on Wednesday, but some analysts weren’t quite ready to pronounce a turnaround for the chip company, which has thus far been unable to ...

Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...

What if the tool you’ve been using for years is far more powerful than you ever imagined? Excel, often dismissed as “just a spreadsheet program,” has transformed into a data analysis powerhouse ...